Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -0.38% | -2.64% | +42.69% | +99.03% | 67.98B | |
| -2.71% | -2.88% | +35.89% | +80.22% | 64.94B | |
| -0.31% | +6.54% | -12.96% | +377.83% | 27.58B | |
| +0.86% | +1.65% | -7.74% | -13.58% | 26.06B | |
| -1.42% | -4.28% | +31.24% | +13.27% | 25.74B | |
| -1.11% | -0.70% | +22.24% | -17.69% | 20.09B | |
| +1.15% | -14.24% | +219.82% | +381.14% | 17.16B | |
| +0.20% | -4.68% | -6.41% | +560.92% | 14.92B | |
| -0.20% | +8.37% | +55.78% | +165.57% | 14.62B | |
| Average | -0.39% | +1.05% | +42.28% | +182.97% | 31.01B | |
| Weighted average by Cap. | -0.81% | +0.59% | +37.32% | +140.89% |
Employees
51
